Company / Capital Expenditures
INOVIO PHARMACEUTICALS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$487.8K
FY2025
5-year range
$320.9K / $1.5M
FY2021-FY2025
Trend
+52.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $487,832.
Based on SEC 10-K filings.
$487,832 in FY2025 with a 5-year CAGR of -25.2%.
Declined from $1M to $487,832 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -31.5%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -25.2%, indicating a declining trend.
- In FY2025, capital expenditures increased 52.0% year-over-year.
- Peak capital expenditures was recorded in FY2019.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $487.8K | +52.0% |
| FY2024 | $320.9K | -73.9% |
| FY2023 | $1.2M | -19.0% |
| FY2022 | $1.5M | +53.9% |
| FY2021 | $987.9K | -52.6% |
| FY2020 | $2.1M | -79.7% |
| FY2019 | $10.3M | +275.9% |
| FY2018 | $2.7M | -1.5% |
| FY2017 | $2.8M | +101.6% |
| FY2016 | $1.4M | +680.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026